Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines

Stefana Pecher, Beth R. Pflug, Alisa K.W. Brink, Joel B. Nelson

Research output: Contribution to journalArticle

4 Scopus citations


BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10 -6-10-10 M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

Original languageEnglish (US)
Pages (from-to)175-177
Number of pages3
Issue number3
StatePublished - Aug 1 2004
Externally publishedYes


  • Atrasentan
  • Endothelin receptor
  • Endothelin-1
  • PSA
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines'. Together they form a unique fingerprint.

  • Cite this